In four patient-derived xenograft (PDX) CRC models harboring BRAF mutation (CR0004, CR0029, CR2179, CR6289), tunlametinib at dose of 1 mg/kg QD, responded (>79% TGI) with all the models exhibiting significant tumor growth suppression (p < 0.05) (Figures 3H–K). Here, BRAF is linked to neoplasm.